| __timestamp | ADMA Biologics, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9517014 | 79696000 |
| Thursday, January 1, 2015 | 7015946 | 93236000 |
| Friday, January 1, 2016 | 7688238 | 150842000 |
| Sunday, January 1, 2017 | 6229587 | 150643000 |
| Monday, January 1, 2018 | 3926120 | 150252000 |
| Tuesday, January 1, 2019 | 2343848 | 140804000 |
| Wednesday, January 1, 2020 | 5907013 | 34236000 |
| Friday, January 1, 2021 | 3646060 | 35672000 |
| Saturday, January 1, 2022 | 3613764 | 66607000 |
| Sunday, January 1, 2023 | 3300000 | 76363000 |
| Monday, January 1, 2024 | 79048000 |
Unlocking the unknown
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Halozyme Therapeutics, Inc. has consistently outpaced ADMA Biologics, Inc. in R&D investment. From 2014 to 2023, Halozyme's R&D expenses have been, on average, nearly 18 times higher than those of ADMA Biologics. This significant difference highlights Halozyme's aggressive pursuit of innovation, with peaks in 2016 and 2017 where their spending reached over $150 million annually. In contrast, ADMA Biologics' R&D spending peaked in 2014 at approximately $9.5 million, followed by a gradual decline. This disparity in investment may reflect differing strategic priorities or financial capabilities. As the biotech industry continues to grow, understanding these spending patterns provides valuable insights into each company's potential for future breakthroughs.
Eli Lilly and Company or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Merck & Co., Inc. and ADMA Biologics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Teva Pharmaceutical Industries Limited and Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and ADMA Biologics, Inc.
Research and Development Investment: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for ADMA Biologics, Inc. and Iovance Biotherapeutics, Inc.
Research and Development: Comparing Key Metrics for ADMA Biologics, Inc. and Viridian Therapeutics, Inc.